Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 124

1.

Blastic Transformation of a Mantle Cell Lymphoma Presenting as an Enlarging Unilateral Orbital Mass.

De Niear MA, Greer JP, Seegmiller A, Mawn LA.

Ocul Oncol Pathol. 2019 Jun;5(4):245-251. doi: 10.1159/000492832. Epub 2018 Nov 16.

2.

Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry.

Lansigan F, Horwitz SM, Pinter-Brown LC, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Shustov AR, Advani RH, Feldman T, Lechowicz MJ, Smith SM, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM.

Acta Haematol. 2019 Jul 17:1-11. doi: 10.1159/000500666. [Epub ahead of print]

PMID:
31315113
3.

Clinicopathologic correlates of MYD88 L265P mutation and programmed cell death (PD-1) pathway in primary central nervous system lymphoma.

Sethi TK, Kovach AE, Grover NS, Huang LC, Lee LA, Rubinstein SM, Wang Y, Morgan DS, Greer JP, Park SI, Ann Thompson-Arildsen M, Yenamandra A, Vnencak-Jones CL, Reddy NM.

Leuk Lymphoma. 2019 Dec;60(12):2880-2889. doi: 10.1080/10428194.2019.1620942. Epub 2019 Jun 11.

PMID:
31184237
4.

The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study.

Park SI, Horwitz SM, Foss FM, Pinter-Brown LC, Carson KR, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Advani RH, Feldman T, Lechowicz MJ, Smith SM, Lansigan F, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Shustov AR; COMPLETE Investigators.

Cancer. 2019 May 1;125(9):1507-1517. doi: 10.1002/cncr.31861. Epub 2019 Jan 29. Erratum in: Cancer. 2019 Nov 1;125(21):3893.

PMID:
30694529
5.

Brentuximab Vedotin for Stage III or IV Hodgkin’s Lymphoma.

Greer JP.

N Engl J Med. 2018 Apr 19;378(16):1559. doi: 10.1056/NEJMc1802363. No abstract available.

PMID:
29671465
6.

Outcomes of a novel rituximab-based non-myeloablative conditioning regimen for hematopoietic cell transplantation in severe aplastic anemia.

Gatwood KS, Culos KA, Binari LA, Engelhardt BG, Kassim A, Byrne MT, Goodman SA, Chinratanalab W, Sengsayadeth SM, Greer JP, Jagasia M, Savani BN.

Bone Marrow Transplant. 2018 Jun;53(6):795-799. doi: 10.1038/s41409-018-0124-6. Epub 2018 Mar 14. No abstract available.

PMID:
29540851
7.

NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018.

Horwitz SM, Ansell SM, Ai WZ, Barnes J, Barta SK, Choi M, Clemens MW, Dogan A, Greer JP, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Kim YH, Lunning MA, Mehta A, Mehta-Shah N, Oki Y, Olsen EA, Pro B, Rajguru SA, Shanbhag S, Shustov A, Sokol L, Torka P, Wilcox R, William B, Zain J, Dwyer MA, Sundar H.

J Natl Compr Canc Netw. 2018 Feb;16(2):123-135. doi: 10.6004/jnccn.2018.0007.

PMID:
29439173
8.

NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017.

Brown PA, Shah B, Fathi A, Wieduwilt M, Advani A, Aoun P, Barta SK, Boyer MW, Bryan T, Burke PW, Cassaday R, Coccia PF, Coutre SE, Damon LE, DeAngelo DJ, Frankfurt O, Greer JP, Kantarjian HM, Klisovic RB, Kupfer G, Litzow M, Liu A, Mattison R, Park J, Rubnitz J, Saad A, Uy GL, Wang ES, Gregory KM, Ogba N.

J Natl Compr Canc Netw. 2017 Sep;15(9):1091-1102. doi: 10.6004/jnccn.2017.0147.

PMID:
28874594
9.

Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.

Shiuan E, Beckermann KE, Ozgun A, Kelly C, McKean M, McQuade J, Thompson MA, Puzanov I, Greer JP, Rapisuwon S, Postow M, Davies MA, Eroglu Z, Johnson D.

J Immunother Cancer. 2017 Feb 21;5:8. doi: 10.1186/s40425-017-0210-0. eCollection 2017.

10.

Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States.

Hsi ED, Horwitz SM, Carson KR, Pinter-Brown LC, Rosen ST, Pro B, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Collie AM, Gruver AM, Grzywacz BJ, Turakhia S, Shustov AR, Advani RH, Feldman T, Lechowicz MJ, Smith SM, Lansigan F, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM.

Clin Lymphoma Myeloma Leuk. 2017 Apr;17(4):193-200. doi: 10.1016/j.clml.2016.10.001. Epub 2017 Jan 10.

PMID:
28209473
11.

Metabolic Complications Precede Alloreactivity and Are Characterized by Changes in Suppression of Tumorigenicity 2 Signaling.

Johnpulle RA, Paczesny S, Jung DK, Daguindau E, Jagasia MH, Savani BN, Chinratanalab W, Cornell RF, Goodman S, Greer JP, Kassim AA, Sengsayadeth S, Byrne MT, Engelhardt BG.

Biol Blood Marrow Transplant. 2017 Mar;23(3):529-532. doi: 10.1016/j.bbmt.2016.12.627. Epub 2016 Dec 21.

12.

A prospective cohort study of patients with peripheral T-cell lymphoma in the United States.

Carson KR, Horwitz SM, Pinter-Brown LC, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta MA, Shustov AR, Advani RH, Feldman TA, Lechowicz MJ, Smith SM, Lansigan F, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM.

Cancer. 2017 Apr 1;123(7):1174-1183. doi: 10.1002/cncr.30416. Epub 2016 Dec 2.

13.

A phase II randomized study of lenalidomide or lenalidomide and rituximab as maintenance therapy following standard chemotherapy for patients with high/high-intermediate risk diffuse large B-cell lymphoma.

Reddy NM, Greer JP, Morgan DS, Chen H, Park SI, Richards KL.

Leukemia. 2017 Jan;31(1):241-244. doi: 10.1038/leu.2016.255. Epub 2016 Sep 22. No abstract available.

14.

Early stage, bulky Hodgkin lymphoma patients have a favorable outcome when treated with or without consolidative radiotherapy: potential role of PET scan in treatment planning.

Nguyen VT, Pophali PA, Tsai JP, Jagadeesh D, Dean RM, Pohlman B, Morgan DS, Greer JP, Smith MR, Hill BT, Reddy NM.

Br J Haematol. 2017 Nov;179(4):674-676. doi: 10.1111/bjh.14236. Epub 2016 Jul 13. No abstract available.

PMID:
27409578
15.

Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and Rituximab Is Associated with Improved Outcomes Compared with Fludarabine and Busulfan after Allogeneic Stem Cell Transplantation for B Cell Malignancies.

Kennedy VE, Savani BN, Greer JP, Kassim AA, Engelhardt BG, Goodman SA, Sengsayadeth S, Chinratanalab W, Jagasia M.

Biol Blood Marrow Transplant. 2016 Oct;22(10):1801-1807. doi: 10.1016/j.bbmt.2016.06.029. Epub 2016 Jul 1.

16.

Cutaneous manifestations and management of hematologic neoplasms.

Oluwole OO, Zic JA, Douds JJ, Ann Thompson M, Greer JP.

Semin Oncol. 2016 Jun;43(3):370-83. doi: 10.1053/j.seminoncol.2016.02.021. Epub 2016 Feb 23. Review.

PMID:
27178691
17.

Early Th1 immunity promotes immune tolerance and may impair graft-versus-leukemia effect after allogeneic hematopoietic cell transplantation.

Engelhardt BG, Paczesny S, Jung DK, Daguindau E, Jagasia M, Savani BN, Chinratanalab W, Cornell RF, Goodman S, Greer JP, Kassim AA, Sengsayadeth S, Yoder SM, Rock MT, Crowe JE Jr.

Haematologica. 2016 May;101(5):e204-8. doi: 10.3324/haematol.2015.139501. Epub 2016 Jan 27. No abstract available.

18.

Cocaine Use and Liver Disease are Associated with All-Cause Mortality in the Miami Adult Studies in HIV (MASH) Cohort.

Campa A, Martinez SS, Sherman KE, Greer JP, Li Y, Garcia S, Stewart T, Ibrahimou B, Williams OD, Baum MK.

J Drug Abuse. 2016;2(4). pii: 27. doi: 10.21767/2471-853X.100036. Epub 2016 Nov 7.

19.

Acute Lymphoblastic Leukemia, Version 2.2015.

Alvarnas JC, Brown PA, Aoun P, Ballen KK, Barta SK, Borate U, Boyer MW, Burke PW, Cassaday R, Castro JE, Coccia PF, Coutre SE, Damon LE, DeAngelo DJ, Douer D, Frankfurt O, Greer JP, Johnson RA, Kantarjian HM, Klisovic RB, Kupfer G, Litzow M, Liu A, Rao AV, Shah B, Uy GL, Wang ES, Zelenetz AD, Gregory K, Smith C.

J Natl Compr Canc Netw. 2015 Oct;13(10):1240-79.

PMID:
26483064
20.

Alternative intensive induction chemotherapeutic regimens in MYC expressing diffuse large B-cell lymphoma.

Tsai JP, Iams WT, Greer JP, Morgan DS, Li S, Reddy NM.

Leuk Lymphoma. 2015 Mar;56(3):797-800. doi: 10.3109/10428194.2014.928937. Epub 2014 Jul 17. No abstract available.

PMID:
24884316
21.

Hemagglutination during photopheresis.

Mask-Bull L, Likhari SB, Zic JA, Greer JP.

J Am Acad Dermatol. 2014 Mar;70(3):e61-2. doi: 10.1016/j.jaad.2013.10.037. Review. No abstract available.

22.

Six-month freedom from treatment failure is an important end point for acute GVHD clinical trials.

Sengsayadeth S, Savani BN, Jagasia M, Goodman S, Greer JP, Chen H, Chinratanalab W, Kassim AA, Engelhardt BG.

Bone Marrow Transplant. 2014 Feb;49(2):236-40. doi: 10.1038/bmt.2013.157. Epub 2013 Oct 7.

23.

Outcomes of autologous or allogeneic stem cell transplantation for non-Hodgkin lymphoma.

Reddy NM, Oluwole O, Greer JP, Engelhardt BG, Jagasia MH, Savani BN.

Exp Hematol. 2014 Jan;42(1):39-45. doi: 10.1016/j.exphem.2013.09.012. Epub 2013 Oct 2.

24.

Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease.

Bachanova V, Marks DI, Zhang MJ, Wang H, de Lima M, Aljurf MD, Arellano M, Artz AS, Bacher U, Cahn JY, Chen YB, Copelan EA, Drobyski WR, Gale RP, Greer JP, Gupta V, Hale GA, Kebriaei P, Lazarus HM, Lewis ID, Lewis VA, Liesveld JL, Litzow MR, Loren AW, Miller AM, Norkin M, Oran B, Pidala J, Rowe JM, Savani BN, Saber W, Vij R, Waller EK, Wiernik PH, Weisdorf DJ.

Leukemia. 2014 Mar;28(3):658-65. doi: 10.1038/leu.2013.253. Epub 2013 Aug 30.

25.

Prevention and treatment of cancer-related infections.

Baden LR, Bensinger W, Angarone M, Casper C, Dubberke ER, Freifeld AG, Garzon R, Greene JN, Greer JP, Ito JI, Karp JE, Kaul DR, King E, Mackler E, Marr KA, Montoya JG, Morris-Engemann A, Pappas PG, Rolston K, Segal B, Seo SK, Swaminathan S, Naganuma M, Shead DA; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2012 Nov 1;10(11):1412-45.

PMID:
23138169
26.

Superior long-term outcome of patients with early transformation of non-Hodgkin lymphoma undergoing stem cell transplantation.

Reddy N, Oluwole O, Greer JP, Goodman S, Engelhardt B, Jagasia MH, Savani BN.

Clin Lymphoma Myeloma Leuk. 2012 Dec;12(6):406-11. doi: 10.1016/j.clml.2012.07.003. Epub 2012 Sep 14.

27.

Allo-SCT for high-risk AML-CR1 in the molecular era: impact of FLT3/ITD outweighs the conventional markers.

Sengsayadeth SM, Jagasia M, Engelhardt BG, Kassim A, Strickland SA, Goodman S, Lucid C, Vnencak-Jones CL, Greer JP, Savani BN.

Bone Marrow Transplant. 2012 Dec;47(12):1535-7. doi: 10.1038/bmt.2012.88. Epub 2012 Jun 4.

PMID:
22659680
28.

Prevalence and risk factors associated with development of ocular GVHD defined by NIH consensus criteria.

Jacobs R, Tran U, Chen H, Kassim A, Engelhardt BG, Greer JP, Goodman SG, Clifton C, Lucid C, Vaughan LA, Savani BN, Jagasia M.

Bone Marrow Transplant. 2012 Nov;47(11):1470-3. doi: 10.1038/bmt.2012.56. Epub 2012 Apr 9.

PMID:
22484321
29.

Long-term outcome after autologous or allogeneic stem cell transplantation in patients with recurrent follicular lymphoma.

Reddy N, Greer JP, Goodman S, Engelhardt B, Oluwole O, Jagasia MH, Savani BN.

Bone Marrow Transplant. 2012 Oct;47(10):1318-20. doi: 10.1038/bmt.2012.10. Epub 2012 Feb 13.

30.

Consolidative therapy with stem cell transplantation improves survival of patients with mantle cell lymphoma after any induction regimen.

Reddy N, Greer JP, Goodman S, Kassim A, Morgan DS, Chinratanalab W, Brandt S, Englehardt B, Oluwole O, Jagasia MH, Savani BN.

Exp Hematol. 2012 May;40(5):359-66. doi: 10.1016/j.exphem.2012.01.012. Epub 2012 Jan 21.

31.

Immunomodulatory nonablative conditioning regimen for B-cell lymphoid malignancies.

Chinratanalab W, Reddy N, Greer JP, Morgan D, Engelhardt B, Kassim A, Brandt SJ, Jagasia M, Goodman S, Savani BN.

Exp Hematol. 2012 Jun;40(6):431-5. doi: 10.1016/j.exphem.2012.01.014. Epub 2012 Jan 21.

32.

Toxicities and outcomes among septuagenarians and octogenarians with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy.

Huntington SF, Talbott MS, Greer JP, Morgan DS, Reddy N.

Leuk Lymphoma. 2012 Aug;53(8):1461-8. doi: 10.3109/10428194.2012.658793. Epub 2012 Mar 1.

PMID:
22260160
33.

Genetic variation in donor CTLA-4 regulatory region is a strong predictor of outcome after allogeneic hematopoietic cell transplantation for hematologic malignancies.

Jagasia M, Clark WB, Brown-Gentry KD, Crawford DC, Fan KH, Chen H, Kassim A, Greer JP, Engelhardt BG, Savani BN.

Biol Blood Marrow Transplant. 2012 Jul;18(7):1069-75. doi: 10.1016/j.bbmt.2011.12.518. Epub 2011 Dec 13.

34.

Genetic variation in recipient B-cell activating factor modulates phenotype of GVHD.

Clark WB, Brown-Gentry KD, Crawford DC, Fan KH, Snavely J, Chen H, Savani BN, Kassim A, Greer JP, Schuening FG, Engelhardt BG, Jagasia MH.

Blood. 2011 Jul 28;118(4):1140-4. doi: 10.1182/blood-2010-09-310011. Epub 2011 May 31.

PMID:
21628416
35.

Early lymphocyte reconstitution is associated with improved transplant outcome after cord blood transplantation.

Tedeschi SK, Jagasia M, Engelhardt BG, Domm J, Kassim AA, Chinratanalab W, Greenhut SL, Goodman S, Greer JP, Schuening F, Frangoul H, Savani BN.

Cytotherapy. 2011 Jan;13(1):78-82. doi: 10.3109/14653249.2010.495114. Epub 2010 Jun 30.

PMID:
20586668
36.

Regulatory T cell expression of CLA or α(4)β(7) and skin or gut acute GVHD outcomes.

Engelhardt BG, Jagasia M, Savani BN, Bratcher NL, Greer JP, Jiang A, Kassim AA, Lu P, Schuening F, Yoder SM, Rock MT, Crowe JE Jr.

Bone Marrow Transplant. 2011 Mar;46(3):436-42. doi: 10.1038/bmt.2010.127. Epub 2010 May 31.

37.

Natural killer-cell neoplasms.

Greer JP, Mosse CA.

Curr Hematol Malig Rep. 2009 Oct;4(4):245-52. doi: 10.1007/s11899-009-0032-3. Review.

PMID:
20425414
38.

Primary bone lymphoma: a set of unique problems in management.

Reddy N, Greer JP.

Leuk Lymphoma. 2010 Jan;51(1):1-2. doi: 10.3109/10428190903470877. No abstract available.

PMID:
20055655
39.

Classic and overlap chronic graft-versus-host disease (cGVHD) is associated with superior outcome after extracorporeal photopheresis (ECP).

Jagasia MH, Savani BN, Stricklin G, Engelhardt B, Kassim A, Dixon S, Chen H, Chinratanalab W, Goodman S, Greer JP, Schuening F.

Biol Blood Marrow Transplant. 2009 Oct;15(10):1288-95. doi: 10.1016/j.bbmt.2009.06.007. Epub 2009 Aug 3.

40.

High-dose chemotherapy followed by autologous stem cell transplantation for relapsed or refractory Hodgkin lymphoma: prognostic features and outcomes.

Engelhardt BG, Holland DW, Brandt SJ, Chinratanalab W, Goodman SA, Greer JP, Jagasia MH, Kassim AA, Morgan DS, Ruffner KL, Schuening FG, Wolff S, Bitting R, Sulur P, Stein RS.

Leuk Lymphoma. 2007 Sep;48(9):1728-35.

PMID:
17786708
41.

Open-label pilot study of combination therapy with rosiglitazone and bexarotene in the treatment of cutaneous T-cell lymphoma.

Sepmeyer JA, Greer JP, Koyama T, Zic JA.

J Am Acad Dermatol. 2007 Apr;56(4):584-7. Epub 2006 Dec 20.

PMID:
17184879
42.

Therapy of peripheral T/NK neoplasms.

Greer JP.

Hematology Am Soc Hematol Educ Program. 2006:331-7. Review.

PMID:
17124080
43.
44.

Non-Hodgkin's lymphoma involving the liver: clinical and therapeutic considerations.

Salmon JS, Thompson MA, Arildsen RC, Greer JP.

Clin Lymphoma Myeloma. 2006 Jan;6(4):273-80. Review.

PMID:
16507204
45.

Pegfilgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplant: phase II study.

Jagasia MH, Greer JP, Morgan DS, Mineishi S, Kassim AA, Ruffner KL, Chen H, Schuening FG.

Bone Marrow Transplant. 2005 Jun;35(12):1165-9.

PMID:
15880129
46.

2-deoxy-2-[F-18]fluoro-D-glucose imaging with positron emission tomography for initial staging of Hodgkin's disease and lymphoma.

Delbeke D, Martin WH, Morgan DS, Kinney MC, Feurer I, Kovalsky E, Arrowsmith T, Greer JP.

Mol Imaging Biol. 2002 Jan;4(1):105-14.

PMID:
14538054
47.

FDG PET in the follow-up management of patients with newly diagnosed Hodgkin and non-Hodgkin lymphoma after first-line chemotherapy.

Lavely WC, Delbeke D, Greer JP, Morgan DS, Byrne DW, Price RR, Hallahan DE.

Int J Radiat Oncol Biol Phys. 2003 Oct 1;57(2):307-15.

PMID:
12957239
48.

Large B-cell lymphoma of the leg: clinical and pathologic characteristics in a North American series.

Brogan BL, Zic JA, Kinney MC, Hu JY, Hamilton KS, Greer JP.

J Am Acad Dermatol. 2003 Aug;49(2):223-8.

PMID:
12894069
49.

Peripheral T-cell lymphomas: clinical features and prognostic factors of 92 cases defined by the revised European American lymphoma classification.

Arrowsmith ER, Macon WR, Kinney MC, Stein RS, Goodman SA, Morgan DS, Flexner JM, Cousar JB, Jagasia MH, McCurley TL, Greer JP.

Leuk Lymphoma. 2003 Feb;44(2):241-9. Review.

PMID:
12688340
50.

T cell and NK cell lymphoproliferative disorders.

Greer JP, Kinney MC, Loughran TP Jr.

Hematology Am Soc Hematol Educ Program. 2001:259-81. Review.

PMID:
11722988

Supplemental Content

Loading ...
Support Center